Ludwig Institute for Cancer Research Limited

Benoit Van Den Eynde

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Etienne De Plaen

Catia Traversari

Beatrice Gaugler

Christophe Lurquin

Olivier DeBacker

Aline Van Pel

Pierre Van Den Bruggen

Patrick Chomez

Thierry Boon

Béatrice Guagler

Pierre G Coulie

Maha Ayyoub

Jean Edouard Gairin

Bernard Monsarrat

Wenbin Ma

Christophe Lurguin

Catherine Germeau

Olivier De Backer

Francis Brasseur

Bernard Lethe

Pedro Romero

Etienne DePlaen

B&eacute;atrice Guagler

Nathalie Brouwenstijn

Nathalie Vigneron

Peter Schrier

Thierry Boon Falleur

Leonora Heidecker

Honor&eacute; Mazarguil

Christoph Lurquin

Honore Mazarguil

Francis Basseur

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x2203;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

MAGE-C2 antigenic peptides and uses thereof

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

The invention relates to new members of the GAGE family referred to as GAGE-7B and GAGE-8. There are differences between these two molecules and the previously described members of the GAGE family on the genomic DNA, complementary DNA, and amino acid level.

Isolated GAGE-7B and 8 proteins

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x3b2;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated proteins MAGE-4 and MAGE-41

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-4 and 41. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-6. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof

The invention relates to nucleic acid molecules which encode members of the GAGE family of tumor rejection antigen precursors and their use.

Isolated nucleic acid molecules which encode GAGE genes and uses thereof

The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

Mage-A12 antigenic peptides and uses thereof

Human melanoma cells bear antigens that are recognized by autologous CD8 cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.

Structurally modified peptides that are resistant to peptidase degradation

Methods for treating a disorder by using Mage-3 or Mage-3 related materials

Isolated nucleic acid molecules are described, which have complements that hybridize to a nucleic acid molecule referred to as MAGE-2. The isolated nucleic acid molecules are expressed in some melanoma cells, as well as other types of cancer cells. The invention also relates to nucleic acid molecules which encode fragments of the proteins encoded by these nucleic acid molecules, and nucleic acid molecules which encode the ultimate product, the so-called tumor rejection antigens.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereof

Isolated, truncated nucleic acid which are members of the gage, and uses thereof

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

Growing community of inventors

Brussels, Belgium

Benoit Van Den Eynde